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Background: Considerable controversy exists regarding the contribution of mineral/bone 
metabolism abnormalities to the association between cardiovascular diseases (CVDs) and 
osteoporotic fractures.
Aims and methods: To determine the relationships between mineral/bone metabolism 
biomarkers and CVD in 746 older patients with hip fracture, clinical data were recorded and 
serum concentrations of parathyroid hormone (PTH), 25-hydroxyvitamin D, calcium, phosphate, 
magnesium, troponin I, parameters of bone turnover, and renal, liver, and thyroid functions 
were measured.
Results: CVDs were diagnosed in 472 (63.3%) patients. Vitamin D deficiency was similarly 
prevalent in patients with (78.0%) and without (82.1%) CVD. The CVD group had significantly 
higher mean PTH concentrations (7.6 vs 6.0 pmol/L, P , 0.001), a higher prevalence of second-
ary hyperparathyroidism (SPTH) (PTH . 6.8 pmol/L, 43.0% vs 23.3%, P , 0.001), and excess 
bone resorption (urinary deoxypyridinoline corrected by creatinine [DPD/Cr] . 7.5 nmol/µmol, 
87.9% vs 74.8%, P , 0.001). In multivariate regression analysis, SHPT (odds ratio [OR] 2.6, 
P = 0.007) and high DPD/Cr (OR 2.8, P = 0.016) were independent indictors of CVD. Compared 
to those with both PTH and DPD/Cr in the normal range, multivariate-adjusted ORs for the 
presence of CVD were 17.3 (P = 0.004) in subjects with SHPT and 9.7 (P , 0.001) in patients 
with high DPD/Cr. CVD was an independent predicator of SHPT (OR 2.8, P = 0.007) and excess 
DPD/Cr (OR 2.5, P = 0.031). CVD was predictive of postoperative myocardial injury, while 
SHPT was also an independent predictor of prolonged hospital stay and in-hospital death.
Conclusion: SHPT and excess bone resorption are independent pathophysiological media-
tors underlying the bidirectional associations between CVD and hip fracture, and therefore are 
important diagnostic and therapeutic targets.
Keywords: cardiovascular disease, hip fracture, PTH, 25(OH)D, secondary  hyperparathyroidism, 
bone turnover, mineral metabolism
Introduction
There is little doubt that cardiovascular diseases (CVDs) and osteoporotic fractures 
are two important public health-care problems worldwide with a high impact on 
morbidity and mortality and increasing prevalence as the population ages. Although 
there are similarities in bone formation and vascular calcification and both disorders 
share several common risk factors (aging, female sex, low physical activity,  smoking, 
alcohol overuse, renal and metabolic diseases),1 traditionally they are regarded as 
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separate but coexisting diseases.2 In the last decade, emerg-
ing data suggest a positive association between CVD and 
osteoporosis beyond these factors and indicate that this link 
may have common underlying biological mechanisms.3–5 
However, there is still a considerable amount of controversial 
literature on this important topic. Many studies report that low 
bone mineral density (BMD) or bone mass, independently 
of age and classical cardiovascular risk factors, is related to 
increased cardiovascular morbidity,4,6–8 especially vascular 
calcification,5,9,10 as well as increased cardiovascular and 
all-cause mortality.11,12 Conversely, bone loss and fracture 
risk is significantly increased in subjects with CVD.13–16 In 
other studies, however, no significant associations between 
BMD and CVD or mortality were observed.17,18 Peripheral 
arterial disease was not associated with risk of hip fracture 
(HF) during a 21-year follow-up.19
Among several potential pathophysiological mechanisms 
linking CVD and osteoporotic fractures, dysregulation in 
mineral and bone metabolism appears as the most important, 
but published data are conflicting. Disturbances in mineral 
and bone metabolism well established in osteoporosis have 
been implicated in the pathogenesis of CVD. These include 
vitamin D deficiency,20–26 abnormalities in serum levels of 
parathyroid hormone (PTH),27–34 calcium and phosphorus 
homeostasis,35–40 and in bone-turnover markers.41–46 Other 
researchers, however, did not support these findings and con-
cluded that the evidence for association of these parameters 
and CVD is currently insufficient.35,40,41,47–50 In one study, for 
example, the development of incident coronary artery disease 
(CAD) in men without chronic kidney disease (CKD) was 
not associated with PTH, phosphorus, or fibroblast growth 
factor 23 (FGF23).49 The contribution and relative importance 
of specific abnormalities in mineral/bone metabolism in the 
genesis of CVD remain unclear.
The relationship between CVD and HF, the most dev-
astating consequence of osteoporosis, remains uncertain. 
Although CVDs are the main causes of morbidity and death 
after HF surgery,51–53 their prevalence in patients with HF has 
not been reported. Previous studies have focused mostly on 
individual biomarkers of mineral or bone metabolism, and 
were often limited to women or patients with HF, or subjects 
with CVD. To our knowledge, no previous investigation has 
simultaneously evaluated parameters of mineral and bone 
metabolism in older HF patients with respect to CVDs.
The aims of this study of a cohort of consecutive older 
patients with osteoporotic HF were (1) to examine the 
prevalence of CVDs, (2) to compare the markers of min-
eral and bone metabolism in those with and without CVD, 
(3) to determine whether these factors explain similarities 
and differences between the two groups, and (4) to estimate 
the contribution of CVD and mineral/bone biomarkers to 
short-term outcomes.
Materials and methods
Study patients
A total of 847 consecutive patients aged 60 years and older 
who were admitted to the Canberra Hospital with low-trauma 
HF and underwent surgery were investigated. After the 
exclusion of 86 patients with pathological HF (metastatic 
bone cancer, multiple myeloma, Paget’s disease) or primary 
hyperparathyroidism and 15 patients in whom data were 
incomplete, a total of 746 patients (536 women and 210 men) 
were included in the analysis.
All patients or their guardians gave informed consent to 
undergo examination and surgical treatment. The study was 
conducted according to the Helsinki Declaration and approved 
by the regional Human Research Ethics Committee.
Clinical data collection
In all patients, a detailed medical history and full physical 
examination was performed. The presence of comorbidi-
ties with a focus on CVD (hypertension, CAD, previous 
myocardial infarction, stroke or transient ischemic attack, 
atrial fibrillation, peripheral vascular disease, and congestive 
heart failure) was identified based on clinical manifestations, 
review of hospital medical records, physicians’ progress 
notes/letters, and medications prescribed. The data collected 
prospectively included medical, demographic, lifestyle, and 
residential characteristics, as well as in-hospital manage-
ment, perioperative complications, and short-term outcomes 
recorded.
Outcome measures included (1) postoperative myo-
cardial injury as defined by cardiac troponin I (cTnI) rise, 
(2) prolonged length of stay (LOS) ($20 days), (3) discharge 
to a permanent residential care facility for patients who were 
admitted from home, and (4) all-cause in-hospital death.
Sample collection and laboratory analyses
In each patient, venous blood and second morning urine 
samples were collected under standardized conditions after 
a 12-hour overnight fast, usually within 24 hours after 
arrival at the emergency department. After centrifugation 
of blood, one serum sample as well as the urine sample 
were frozen and stored at −70°C until further analysis. The 
following biochemical parameters of mineral and bone 
metabolism were determined: serum concentrations of 
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25- hydroxyvitamin D (25[OH]D), intact PTH, total calcium, 
phosphate, magnesium, osteocalcin (OC), and bone-specific 
alkaline phosphatase (BAP) as markers of bone formation 
and urinary concentrations of deoxypyridinoline (DPD/Cr), 
and cross-linked N-telopeptide of type 1 collagen (NTx) as 
markers of bone resorption (both corrected for urinary crea-
tinine concentrations in the same sample).
Serum 25(OH)D was measured by radioimmunoassay kit 
(Dia Sorin, Stillwater, MN, USA) and intact PTH by two-site 
chemiluminescent enzyme-linked immunoassay on DPC 
Immulite 2000 (Diagnostic Products, Los Angeles, CA, USA). 
Serum OC was determined by electrochemiluminescent 
immunoassay (Elecsys 1010; Roche Diagnostics, IN, USA), 
serum BAP by Metra BAP enzyme-linked immunosorbent 
assay (Quidel, San Diego, CA, USA), urinary cross-linked 
N-telopeptide of type I collagen (NTx) by enzyme-linked 
immunosorbent assay (Wampole Labs, Princeton, NJ, USA), 
and urinary DPD by two-site chemiluminescent enzyme-
labeled immunoassay (DPC Immulite 2000; Diagnostic 
Products). All samples were analyzed with commercially 
available kits of the same lot number according to the manu-
facturer’s protocol, and blind to any clinical information. In 
these methods, both the intra- and interassay coefficient of 
variations (CVs) ranged from 2.1% to 12.7%.
On the day of arrival and blood sampling, the follow-
ing routine laboratory tests also were performed: full blood 
count, creatinine, urea nitrogen, albumin, liver and thyroid 
function tests (by standard automated methods), and serum 
cTn, by two-step chemiluminescent microparticle immuno-
assay (Chemiflex; Abbott Labs, Mississauga, ON, Canada). 
Full blood count and serum cTnI were also assessed within 
24 hours postoperatively and subsequently if clinically 
indicated. Serum calcium concentrations were corrected for 
serum albumin. Estimated glomerular filtration rate (eGFR) 
was calculated using the Modification of Diet in Renal Dis-
ease study equation.54
For the analyses, deficiency of vitamin D was defined 
as 25(OH)D , 50 nmol/L and moderate–severe deficiency 
as 25(OH)D , 25 nmol/L, based on current guidelines. 
 Secondary hyperparathyroidism (SHPT) was defined as 
elevated serum PTH (.6.8 pmol/L, the upper limit of the 
laboratory reference range). For levels of bone-turnover 
markers, we used the standard laboratory reference ranges 
and data provided by the manufacturer.
Statistics
Stata software version 10 (StataCorp, College Station, TX, 
USA) was used for all statistical analyses. Descriptive  statistics 
included means (± standard deviation of mean) for con-
tinuous variables or percentages for categorical  variables. 
 Comparisons between groups were performed using analysis 
of variance and Student’s t-test (for continuous variables) 
and χ2 test (for categorical variables). Pearson’s correlation 
coefficient with log-transformed data (to achieve normal 
distribution) was used to study the correlation between 
variables; Bonferroni and Sidak adjustments for multiplicity 
were performed. Univariate and multivariate linear regres-
sion analyses were performed to determine the associations 
between different parameters of mineral and bone metabo-
lism and presence of CVD as well as short-term outcomes; 
all potential confounding variables (demographic, clinical, 
biochemical) with statistical significance # 0.15 on uni-
variate analyses were included in multivariate analysis. To 
quantify the significance of multicollinearity phenomena 
in regression analysis, the variance inflation factor was 
calculated. Two-sided P , 0.05 values were considered 
statistically significant.
Results
General characteristics of study patients
Demographic and clinical characteristics of the study patients 
are shown in Table 1. A history of CVD was present in 472 
(63.3%) of 746 patients included in the study. This group was 
older (on average 2.2 years) and had a higher proportion of 
patients with American Society of Anesthesiologists (ASA) 
score $ 3 (+22%) and renal impairment (CKD $ 3, +10.9%). 
No significant differences between patients with and without 
CVD were observed in regard to sex, residential status, use of 
walking device, current and former smoking status, alcohol 
consumption, dementia, type 2 diabetes mellitus, chronic 
obstructive pulmonary disease, Parkinson’s disease, thyroid 
dysfunction, anemia, or hypoalbuminemia.
The group with CVD comprised 337 (45.2% of the total 
cohort) patients with hypertension, 171 (22.9%) with CAD, 
including 39 (5.2%) with a previous myocardial infarction, 
100 (13.4%) with history of stroke, 55 (7.4%) with a his-
tory of transient ischemic attack, and 99 (13.2%) with atrial 
fibrillation (AF). Among the patients with CVDs, one con-
dition was present in 290 (61.4%), two in 121 (25.6%) and 
three or more in 66 (14.0%) subjects. Chronic heart failure 
was diagnosed in 384 (59.5% of the total cohort, 81.4% of 
patients with CVD). Hypertension was associated with CAD 
(Pearson correlation r = 0.146, P = 0.014) and history of 
stroke (r = 0.186, P = 0.002). CAD was also associated with 
history of stroke (r = 0.221, P = 0.033) and AF (r = 0.221, 
P , 0.001).
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Table 1 Socio-demographic and clinical characteristics of older patients with hip fracture included in the study (n = 746)
Characteristic CVD P-value
Yes (n = 472) No (n = 274)
Age, years (mean ± SD) 83.0 ± 7.1 80.8 ± 9.2 0.032
Females, % 73.7 68.7 0.448
Admitted from long term rCF, % 28.7 33.7 0.386
Dementia, % 22.4 30.3 0.151
Diabetes mellitus, % 15.2 15.3 0.967
COPD, % 11.2 11.1 0.987
Parkinson’s disease, % 3.4 4.0 0.768
Current smoker, % 3.9 5.0 0.654
Ex-smoker, % 10.1 14.1 0.307
Alcohol overuser,* % 5.6 4.0 0.572
User of walking device, % 37.4 30.9 0.233
ASA score $ 3 79.3 57.3 0.001
Cervical HF, % 53.1 48.5 0.543
Hemoglobin , 120 g/L, % 65.4 62.6 0.745
Albumin , 33 g/L, % 25.1 34.3 0.103
eGFr , 60 mL/minute/1.73 m2, % 48.3 37.4 0.036
eGFr , 30 mL/minute/1.73 m2, % 5.1 5.2 1.000
Notes: *Three or more times per week. Values in bold indicate statistically significant P values.
Abbreviations: CVD, cardiovascular disease; rCF, residential care facility; COPD, chronic obstructive pulmonary disease; HF, hip fracture; eGFr, estimated glomerular 
filtration rate; ASA, American Society of Anesthesiologists; SD, standard deviation.
Among patients with CVD, angiotensin-converting 
enzyme (ACE) inhibitors were used by 26.5%, angiotensin 
2-receptor blockers (ARBs) by 23.3%, beta blockers by 
27.4%, calcium-channel blockers by 12.7%, and statins by 
21.5%. Antiosteoporotic medications were used as follows: 
vitamin D supplement by 19.1% of patients with CVD and 
17.7% without CVD, calcium supplement by 22.5% and 
19.9%, bisphosphonate by 13.5% and 12.3%, and raloxifene 
by 1.12% and 0.72%, respectively.
Parameters of mineral and bone 
metabolism in patients  
with and without cardiovascular disease
The mean values of serum 25(OH)D concentrations in the 
group of patients with CVD in total and with each analyzed 
cardiovascular condition separately were low and did not 
differ from patients without CVD (Table 2). In contrast, 
serum PTH levels were significantly higher in all groups with 
CVD compared to non-CVD patients. Patients with hyperten-
sion and CAD also had higher serum phosphate levels, and 
subjects with CAD, history of stroke, and AF demonstrated 
higher magnesium levels.
The prevalence of vitamin D def iciency (25[OH]
D , 50 nmol/L) was high in both patients without CVD and 
in the total group with CVD (82.1% and 78.0%, respectively), 
but slightly lower in patients with CAD (73.1%, P = 0.032) 
and history of stroke (68.0%, P = 0.006). The percentage of 
patients with moderate–severe vitamin D deficiency (25[OH]
D , 25 nmol/L) did not differ between groups either: 28.9% 
in the non-CVD group and 31.2% among subjects with CVD, 
including those with hypertension (34.0%), CAD (33.3%), 
history of stroke (27.0%), and AF (34.5%).
Conversely, compared to patients without CVD, the pro-
portion of subjects with elevated PTH levels (.6.8 pmol/L) 
indicating SHPT was about two times higher among the 
patients with CVD (43% vs 23.3%, P , 0.001), and the 
highest percentages were observed in patients with CAD 
(53.8%) and history of stroke (51.0%), despite the lower 
prevalence of vitamin D deficiency in these two groups. 
Among patients with both vitamin D deficiency and 
elevated PTH, there was a higher prevalence of subjects 
with CVD (35.5% vs 21.1%, P = 0.024), including those 
with hypertension (37.7%, P = 0.012), CAD (46.4%, 
P = 0.003), history of stroke (37.8%, P = 0.0.13), and AF 
(35.5%, P = 0.041). Of 267 patients (35.8% of the total 
cohort) with SHPT, 203 (76.03%) had CVD. Subjects with 
CVD and SHPT compared to those with normal PTH status 
(12.3 ± 1.8 vs 4.0 ± 1.6 pmol/L) had a lower level of serum 
calcium (2.24 ± 0.12 vs 2.30 ± 0.12; P = 0.002) and eGFR 
(54.4 ± 24.6 vs 68.1 ± 20.0 mL/minute/1.73 m2; P , 0.001), 
but there were no differences in age or other biochemical 
and clinical parameters, except a higher proportion of 
patients with ASA $ 3 among the first group (88.3% vs 
73.9%; P = 0.038).
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Table 2 Parameters of mineral and bone metabolism in older hip-fracture patients with and without cardiovascular disease
No CVD  
(n = 274)
Hypertension  
(n = 337)
CAD  
(n = 171)
Stroke  
(n = 100)
AF  
(n = 99)
Any CVD  
(n = 472)
Age, years 80.8 (9.2) 82.4 (7.3)* 83.9 (7.1)*** 83.9 (6.4)*** 83.8 (6.3)*** 83.0 (7.1)***
25(OH)D, nmol/L 36.5 (18.9) 36.1 (17.5) 39.1 (18.1) 40.1 (20.0) 36.8 (13.3) 37.8 (18.1)
PTH, pmol/L 6.0 (4.3) 7.2 (5.1)** 9.9 (8.5)*** 10.0 (7.5)*** 10.3 (7.1)*** 7.6 (6.2)***
Calcium, mmol/L 2.27 (0.13) 2.29 (0.13) 2.27 (0.12) 2.26 (0.10) 2.26 (0.12) 2.28 (0.13)
Phosphate, mmol/L 0.91 (0.27) 0.99 (0.26)** 1.02 (0.56)** 0.86 (0.29) 0.87 (0.34) 0.99 (0.56)*
Magnesium, mmol/L 0.77 (0.11) 0.76 (0.14) 0.81 (0.12)*** 0.80 (0.19)* 0.81 (0.13)** 0.78 (0.14)
Osteocalcin, ng/mL 17.4 (16.0) 16.6 (10.6) 20.6 (22.9) 16.2 (14.5) 17.5 (13.4) 17.6 (15.2)
BAP, IU 26.3 (17.8) 26.6 (12.6) 27.6 (11.8) 26.2 (11.3) 25.5 (8.8) 26.8 (12.2)
Osteocalcin/BAP ratio 0.79 (0.88) 0.76 (0.70) 0.77 (0.86) 0.59 (0.37) 0.76 (0.58) 0.74 (0.67)
DPD/Cr, nmol/µmol 11.6 (5.6) 12.1 (4.8) 15.3 (13.4)*** 14.8 (7.2)*** 13.6 (7.1)** 13.3 (8.2)***
NTx/Cr, nmol/µmol 162 (174.9) 135.4 (104.3) 214.3 (258.1) 154.7 (154.5) 127.8 (97.3) 157.2 (163.7)
25(OH)D , 50 nmol/L, n (%) 225 (82.1) 277 (87.2) 125 (73.1)* 68 (68.0)** 85 (85.9) 368 (78.0)
PTH . 6.8 pmol/L, n (%) 64 (23.3) 146 (43.3)*** 92 (53.8)*** 51 (51.0)*** 42 (42.4)*** 203 (43.0)***
DPD/Cr . 7.5 nmol/µmol, n (%) 205 (74.8) 296 (87.8)*** 157 (91.8)*** 94 (94.0)*** 90 (90.9)** 415 (87.9)***
Notes: *P , 0.05; **P , 0.01; ***P , 0.001. Data are presented as means (standard deviation) for continuous variables and as n (%) for categorical. Calcium was albumin-
corrected. Statistically significant differences in variables in patients with CVD compared to those without CVD are shown in bold.
Abbreviations: CVD, cardiovascular disease; AF, atrial fibrillation; 25(OH)D, 25-hydroxyvitamin D; PTH, parathyroid hormone; BAP, bone-specific alkaline phosphatase; 
DPD/Cr, urinary deoxypyridinoline adjusted for creatinine; NTx/Cr, urinary cross-linked N-telopeptides of type I collagen adjusted for creatinine; CHD, coronary heart 
disease.
The mean serum levels of both bone-formation mark-
ers (OC and BAP) and the OC/BAP ratios (indicator of 
osteoblastic differentiation) did not differ among the groups 
with and without CVD. Low OC levels (,14 ng/mL, below 
reference range) were observed in approximately half of the 
patients (53.1% without CVD and 51.7% with CVD), while 
low BAP levels (,14 IU) occurred in 9.7% (13.3% and 7.7%, 
respectively). The different behaviors of OC and BAP, each 
of which reflects different aspects of bone metabolism and 
different stages of osteoblastic differentiation, have previ-
ously been observed in other clinical settings.55
The urinary excretion of DPD adjusted for creatinine 
(DPD/Cr), a bone-resorption marker, was significantly 
higher in patients with CAD (31.9%), history of stroke 
(27.6%), atrial fibrillation (17.2%), and in the total group 
with CVD (14.7%). However, the association between 
CVD and urinary NTx/Cr, the collagen product which 
resembles DPD, was not significant. In other studies, these 
two bone-resorption markers have also shown clinically 
distinct properties.56–58 The prevalence of elevated DPD/
Cr (.7.5 nmol/µmol) was significantly higher in the group 
with CVD (87.9% vs 74.8%; P , 0.001), including those 
with hypertension (87.8%, P , 0.001), CAD (91.8%, 
P , 0.001), history of stroke (94%, P , 0.001), and AF 
(90%, P = 0.002). Among patients with CVD and high 
DPD/Cr excretion compared to those with DPD/Cr in the 
normal range, the proportion of subjects with SHPT (40.9% 
vs 66.7%; P = 0.038) and low serum OC (49.6% vs 83.3%; 
P = 0.007) was lower.
With an increasing number of CVDs, there was a gradient 
increase in mean levels of serum PTH (in subjects with one 
CVD 7.4 pmol/L, with two CVDs 9.1 pmol/L, and with three 
or more CVDs 10.2 pmol/L; P for trend = 0.001), as well as 
in the prevalence of secondary hyperparathyroidism (35.5%, 
45.5%, and 60.0%, respectively; P for trend = 0.001). 
 Similarly, increasing the number of CVDs increased the mean 
levels of urinary DPD/Cr (12.1, 14.3, and 15.8 nmol/µmol, 
respectively; P for trend = 0.030) and the proportion of 
patients with abnormally high bone-resorption status (83.8%, 
88.0%, and 95.2%, respectively; P for trend = 0.016).
Correlations between biomarkers  
of mineral and bone metabolism  
by cardiovascular disease
To evaluate further the associations between CVD and altered 
parameters of mineral and bone metabolism in HF patients, 
Pearson correlation coefficients were estimated separately in 
subjects with and without CVD. Values for PTH, 25(OH)D, 
mineral- and bone-metabolism parameters, and eGFR were 
logarithmically transformed before analysis. This analysis 
revealed similarities and differences in patients with and 
without CVD. In both groups, serum PTH levels were posi-
tively correlated with age and inversely with serum calcium, 
eGFR, and cervical type of HF (Table 3).
However, only in patients with CVD, PTH correlated pos-
itively with BAP, troponin I, and in-hospital death, while only 
in the non-CVD group higher PTH levels were significantly 
associated with female sex and dementia. BAP correlated 
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Table 3 Pearson correlation coefficients between serum PTH 
levels and selected clinical, mineral, and bone metabolism factors 
in older hip-fracture patients with and without cardiovascular 
disease
With CVD Without CVD
r P r P
Age 0.178 0.017 0.329 0.001
Sex (m) −0.127 0.092 −0.242 0.018
HF type (cervical) −0.148 0.05 −0.225 0.028
Dementia −0.076 0.31 0.229 0.026
Calcium −0.312 ,0.001 −221 0.034
BAP 0.165 0.032 0.072 0.491
eGFr −0.373 ,0.001 −0.249 0.015
Troponin I 0.161 0.036 0.1937 0.056
In-hospital death 0.227 0.002 0.178 0.084
Note: Values for PTH, 25-hydroxyvitamin D, mineral and bone turnover parameters, 
and eGFR were log-transformed. Values in bold indicate statistically significant 
P values.
Abbreviations: PTH, parathyroid hormone; CVD, cardiovascular disease; BAP, 
bone-specific alkaline phosphatase; eGFR, estimated glomerular filtration rate; 
HF, hip fracture.
positively with serum magnesium (r = 0.176, P , 0.022) 
in the CVD group and with calcium (r = 0.349, P , 0.001) 
and phosphate (r = 0.286, P = 0.049) in patients without 
CVD. Only in the later group, OC correlated positively with 
BAP (r = 0.264, P = 0.009), calcium (r = 0.240, P = 0.020), 
and magnesium (r = 0.279, P = 0.007). In both groups, OC 
correlated inversely with eGFR (r = −0.456, P , 0.001 for 
the CVD group and r = −0.202, P = 0.046 for the non-CVD 
group) and in-hospital death (r = −0.210, P = 0.006 and 
r = −0.254, P = 0.012, respectively). In both groups, DPD/
Cr positively correlated with serum phosphate (r = 0.165, 
P = 0.048 and r = 0.268, P = 0.014, respectively), and the 
two urinary bone-resorption markers (DPD/Cr and NTx/Cr) 
were significantly intercorrelated (r = 0.446, P , 0.001 and 
r = 0.349, P , 0.001, respectively). 25(OH)D correlated 
negatively only with NTx/Cr only in the non-CVD patients 
(r = −0.260, P = 0.021). There was no correlation between 
PTH and resorption markers (DPD/Cr and NTx/Cr), which 
is consistent with previous reports.59,60
Factors associated with cardiovascular 
disease
In univariate analyses of twelve biochemical (25[OH]D, 
PTH, calcium, phosphate, magnesium, OC, BAP, DPD/Cr, 
NTx/Cr, hemoglobin, albumin, eGFR) and seven clinical 
(age, sex, HF type, dementia, smoking, alcohol overuse, 
use of walking device) parameters, presence of CVD was 
significantly associated only with age (OR 1.03, 95% 
confidence interval [CI] 1.00–1.07; P = 0.034), high bone 
resorption  (urinary DPD/Cr . 7.5 nmol/µmol, OR 2.44, 95% 
CI 1.23–4.87; P = 0.011), and elevated serum PTH levels 
(.6.8 pmol/L, OR 2.36, 95% CI 1.35–4.11; P = 0.003). PTH 
as a continuous variable was also associated with CVD (OR 
1.06, 95% CI 1.00–1.13; P = 0.033), indicating that the risk 
of CVD increases by 6% per 1 pmol/L increment in PTH.
To evaluate further whether higher serum PTH levels 
were associated with CVD, and given the wide range of PTH 
in our cohort, age-, sex- and 25(OH)D-adjusted ORs were 
estimated by quartiles of PTH concentration. For the total 
CVD group as well as for each of the four studied diseases 
separately, the adjusted ORs increased with quartiles of 
serum PTH (P for trends , 0.01 in all groups). Compared to 
the first quartile (PTH , 3.5 pmol/L), in the fourth quartile 
(PTH . 8.7 pmol/L) the OR for the total CVD group was 
2.5 times higher (95% CI 1.12–5.61; P = 0.006), and the 
highest values were for CAD (OR 3.34, 95% CI 1.35–8.33; 
P = 0.009) and history of stroke (OR 2.93, 95% CI 1.04–8.21; 
P = 0.011).
Using serum PTH at a cutoff of 6.8 pmol/L, it was pos-
sible to discriminate between presence and absence of CVD 
with a sensitivity of 42.9%, specificity of 75.8%, positive 
predictive value of 76.8% and negative predictive value of 
41.6%, and using PTH . 8.7 pmol/L with 30.5%, 84.2%, 
78.3%, and 39.4%, respectively. A sensitivity of 88.0%, 
specificity of 25.0%, positive predictive value of 66.7%, and 
negative predictive value of 55.0% were yielded using DPD/
Cr . 7.5 nmol/µmol. These data suggest that SPTH (more 
specific) and high bone resorption (more sensitive) may be 
useful indicators of CVD (if previously not diagnosed).
We then examined which factors are independently 
associated with CVD. Multiple logistic regression analysis 
with PTH, 25(OH)D, DPD/Cr, albuminemia, eGFR, smok-
ing status, alcohol consumption, HF type, dementia, and sex 
entered as independent categorical variables and corrected 
for age showed that elevated serum PTH (.6.8 pmol/L), 
high urinary DPD/Cr (.7.5 nmol/µmol), and advanced age 
were the only significant indicators of presence of CVD 
(Table 4), and together explained 32.1% of the variability in 
presence of CVD. Elevated PTH levels were independently 
and significantly associated with each of the analyzed CVDs 
(Table 5), and the OR ranged between 1.91 (for AF) and 
3.43 (for CAD). Of note, in our models we did not include 
medication use (see below) as independent variables, as their 
use was a consequence of presence of CVD.
Further, we examined the unique and combined effects 
of abnormally high PTH and DPD/Cr levels as indicators of 
presence of CVD (Table 6). Compared to subjects with nor-
mal serum PTH and urinary DPD/Cr levels (reference group), 
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(SHPT) and high bone resorption (DPD/Cr . 7.5 nmol/µmol) 
in older HF patients. These models included age, sex, 
CVD (yes/no), dementia (yes/no), type 2 diabetes mellitus 
(yes/no), HF type, smoking status, alcohol consumption, 
eGFR , 60 mL/minute/1.73 m2 (yes/no), albumin , 33 g/L 
(yes/no), OC , 14 ng/mL (yes/no), 25(OH)D, calcium, 
phosphate, magnesium, and DPD/Cr . 7.5 nmol/µmol (in 
the first model) or PTH . 6.8 pmol/L (in the second model) 
as independent variables. Independent predictors of SHPT 
were CVD (any) (OR 2.76, 95% CI 1.30–5.86; P = 0.008), 
renal impairment (OR 4.70, 95% CI 2.10–10.56; P , 0.001), 
female sex (OR 2.42, 95% CI 1.03–5.71; P = 0.043), 25(OH)
D (OR 0.97, 95% CI 0.95–0.99; P = 0.014), serum calcium 
corrected for albumin (OR 0.003, 95% CI 0.0002–0.054; 
P , 0.001), and serum phosphate (OR 4.07, 95% CI 
1.26–13.18; P = 0.019). The combined effect of these factors 
explained 48.7% of the variability in SHPT. These associa-
tions remained significant when the analyses were repeated 
with each CVD separately: OR ranged between 1.7 for AF 
and 2.9 for CAD.
Independent indicators of high bone resorption were the 
presence of CVD (OR 2.57, 95% CI 1.11–6.00; P = 0.028), 
low eGFR (OR 0.19, 95% CI 0.07–0.52; P = 0.001), and 
low OC (OR 6.20, 95% CI 2.23–17.25; P , 0.001), which 
explained 38.3% of the variability in high DPD/Cr. The 
“preventive” effect of renal impairment reflects the fact that 
DPD is mainly released by degradation of peptide-bound 
cross-links through renal metabolism61 and is not directly 
generated from osteoclastic bone resorption.62 Of note, CVD 
emerged as the second-most significant independent predictor 
(after eGFR , 60 mL/minute/1.73 m2) of both SHPT and 
excess bone resorption in this cohort.
Taken together, these data indicate that in older HF 
patients both SHPT and high bone resorption are significant 
independent indicators of the presence of CVD and vice versa. 
The OR for the presence of CVD is 2.68 times higher among 
subjects with SHPT and 2.58 times higher among patients 
with high bone resorption compared to patients without such 
a condition. Furthermore, compared to subjects with both 
PTH and DPD/Cr in the normal range, the OR for presence of 
CVD is 17.3 times higher in patients with SHPT and 5.3 times 
higher in subjects with excess bone resorption. On the other 
hand, CVD predicts SHPT (OR 2.82) and excess bone 
resorption (OR 2.53). These findings suggest bidirectional 
links between CVD and mineral/bone parameters related 
to osteoporosis. As the 25(OH)D levels in patients with 
and without CVD were low and did not differ significantly, 
our results highlight the significance of the independent 
Table 4 Independent factors associated with the presence of 
cardiovascular disease in older hip-fracture patients
OR 95% CI P-value
PTH . 6.8 pmol/L 2.60 1.30–5.20 0.007
DPD/Cr . 7.5 nmol/µmol 2.77 1.21–6.55 0.016
Age 1.04 1.01–1.09 0.046
Notes: Adjustments for age, sex, eGFr , 60 mL/minute/1.73 m2, 25(OH)
D , 50 nmol/L, urinary DPD/Cr . 7.5 nmol/µmol, osteocalcin , 14 ng/mL, 
albumin , 33 g/L, smoking status (current and previous), alcohol consumption 
($3 times per week), dementia, type 2 diabetes mellitus and hip-fracture type. These 
associations remained robust after adjustment for aforementioned confounding 
factors and 25(OH)D , 25 nmol/L (eg, for elevated PTH: Or 2.48, 95% CI 1.25–
4.92; P = 0.009).
Abbreviations: PTH, parathyroid hormone; OR, odds ratio; CI, confidence 
interval; DPD/Cr, urinary deoxypyridinoline adjusted for creatinine; 25(OH)D, 
25-hydroxyvitamin D; eGFR, estimated glomerular filtration rate.
Table 5 Multivariate-adjusted odds ratio for the presence of 
cardiovascular disease in older hip-fracture patients with elevated 
serum parathyroid hormone levels (.6.8 pmol/L)
OR 95% CI P-value
Hypertension 1.97 1.08–3.60 0.028
CAD 3.43 1.60–7.32 0.001
Stroke 2.57 1.07–6.15 0.034
AF 1.91 1.03–3.45 0.048
CVD (total) 2.68 1.36–2.88 0.005
Notes: Adjustments for age, sex, eGFr , 60 mL/minute/1.73 m2, 25(OH)
D , 50 nmol/L, urinary DPD/Cr . 7.5 nmol/µmol, osteocalcin , 14 ng/mL, 
albumin , 33 g/L, smoking status (current and previous), alcohol consumption 
($3 times per week), dementia, type 2 diabetes mellitus and hip-fracture type.
Abbreviations: OR, odds ratio; CI, confidence interval; CVD, cardiovascular 
disease; CAD, coronary artery disease; AF, atrial fibrillation; DPD/Cr, urinary 
deoxypyridinoline adjusted for creatinine; 25(OH)D, 25-hydroxyvitamin D; eGFr, 
estimated glomerular filtration rate.
the age- and sex-adjusted OR for CVD (model 1) was signifi-
cantly greater in patients with high DPD/Cr and normal PTH 
levels (OR 4.26, P = 0.005), but the highest risk of CVD was 
in patients with elevated PTH and both normal (OR 10.27, 
P = 0.004) and high DPD/Cr (OR 7.61, P , 0.001). After 
adjustment for seven additional factors was made, the OR for 
the presence of CVD further increased (model 2, Table 6): 
17.32 in patients only with SHPT, 9.68 in patients with SHPT 
and high DPD/Cr, and 5.33 in subjects only with excess bone 
resorption. These associations are displayed in Figure 1. In 
total, the OR for presence of CVD among HF patients with 
SHPT or excess bone resorption compared to those with both 
parameters in the normal range was 7.54 (Table 6).
Independent factors associated  
with serum PTH elevation  
and high bone resorption
Multivariate logistic regression analyses were performed to 
determine independent factors associated with elevated PTH 
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Table 6 Odds ratios for presence of cardiovascular disease according to serum PTH concentrations as urinary deoxypyridinoline 
excretion in older patients with hip fracture
Parameters Model OR 95% CI P-value
PTH . 6.8 pmol/L and DPD/Cr # 7.5 nmol/µmol 1 10.27 2.11–44.93 0.004
 2 17.32 2.79–107.37 0.002
PTH . 6.8 pmol/L and DPD/Cr . 7.5 nmol/µmol 1 7.61 2.54–22.76 ,0.001
 2 9.68 3.02–31.02 ,0.001
PTH # 6.8 pmol/L and DPD/Cr . 7.5 nmol/µmol 1 4.26 1.55 – 11.70 0.005
 2 5.33 1.83 – 15.50 0.002
PTH . 6.8 pmol/L or DPD/Cr .7.5 nmol/µmol 1 5.37 2.00–14.43 0.001
 2 7.54 2.65–21.42 ,0.001
Notes: The Or compared to the reference group (both PTH and DPD/Cr in the normal range) is shown. Model 1: adjustment for age and sex. Model 2: adjustment for age, 
sex, smoking status, alcohol consumption, dementia, hip-fracture type, eGFr , 60 mL/minute/1.73 m2, 25(OH)D , 50 nmol/L, and albumin , 33 g/L.
Abbreviations: PTH, parathyroid hormone; DPD/Cr, deoxypyridinoline corrected by urinary creatinine; OR, odds ratio; CI, confidence interval; 25(OH)D, 25-hydroxyvitamin 
D; eGFR, estimated glomerular filtration rate.
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Figure 1 Odds ratios for presence of cardiovascular disease in older patients with hip fracture according to serum parathyroid hormone and urinary deoxypyridinoline levels.
Notes: High levels were defined as exceeding the upper limits of normal range: .6.8 pmol/L for serum PTH and .7.5 nmol/µmol for urinary DPD/Cr. Adjustment was made 
for age, sex, smoking status, alcohol consumption, dementia, hip-fracture type, eGFr , 60 mL/minute/1.73 m2, 25(OH)D , 50 nmol/L and albumin , 33 g/L. The odds ratios 
compared to the reference group (both PTH and DPD/Cr in the normal range) are shown.
Abbreviations: PTH, parathyroid hormone; DPD/Cr, deoxypyridinoline corrected by urinary creatinine; 25(OH)D, 25-hydroxyvitamin D; eGFr, estimated glomerular 
filtration rate.
 associations between SHPT, high bone resorption, and CVD, 
supporting the hypothesis that osteoporosis and CVD share 
common biological mechanisms.
PTH and use of cardiovascular 
medications
In order to determine potential effects of different cardiovas-
cular medications on vitamin D and PTH status, the serum 
mean values of 25(OH)D and PTH in patients receiving and 
not receiving such drugs were compared. Table 7 shows 
that if compared with nonusers, serum PTH levels were 
significantly higher in users of ACE inhibitors (65.7%) and 
beta blockers (49.3%), but significantly lower in patients 
receiving calcium channel blockers (34.6%). PTH levels 
did not differ in respect to use of ARBs. No significant 
associations between serum 25(OH)D concentrations and 
use of any of the five classes of cardiovascular medications 
have been found.
Multiple logistic regression analyses with use of the 
aforementioned medications as independent variables and 
controlling for age, sex, CVD, renal impairment, HF type, 
25(OH)D, calcium, phosphate, magnesium, and DPD/Cr 
showed that among these five medication classes only the 
use of ACE inhibitors was significantly and independently 
associated with elevated PTH (SHPT) (OR 3.76, 95% CI 
1.01–14.16; P = 0.049).
Cardiovascular disease and PTH  
as predictors of short-term outcomes
In multivariate regression models that considered age, 
sex, preexisting comorbidities including CAD, hyperten-
sion, history of stroke, AF, dementia, CKD $ 3 stage, 
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ASA score $ 3, and smoking status, having CVD was a 
strong independent predictor of postoperative myocardial 
injury (cTnI rise) (OR 6.13, 95% CI 1.57–24.00; P = 0.009) 
and prolonged hospital stay (LOS . 20 days) (OR 4.27, 95% 
CI 1.53–11.88; P = 0.005). After further adjusting for SHPT, 
vitamin D deficiency, and high urinary DPD/Cr excretion, 
patients with CVD were 2.3 times more likely to develop 
postoperative myocardial injury (OR 2.25, 95% CI 1.10–4.58; 
P = 0.006); however, the association between CVD and 
prolonged length of stay was no longer significant. In fully 
adjusted models (all clinical and laboratory parameters), 
CVD did not predict long-term residential care facility need 
or in-hospital death either. In contrast, SHPT was a strong 
independent predictor of in-hospital mortality (OR 17.39, 
95% CI 3.32–78.63; P , 0.001), LOS . 20 days (OR 2.82, 
95% CI 1.47–5.41; P = 0.002). and myocardial injury (OR 
1.42, 95% CI 1.25–1.88; P , 0.001). This does not mean that 
CVD is unrelated to outcomes. It does imply that SHPT is 
an important pathway contributing to and mediating poorer 
outcomes. Elevated PTH (.6.8 pmol/L) occurred in 76.9% 
of in-hospital deaths, 59.2% of postoperative cTnI rises, and 
in 45.3% of prolonged hospital stays.
Discussion
Main findings
In this study of 746 consecutive older patients with osteo-
porotic (low-trauma) HF, preoperatively CVD was diagnosed 
in 63.3% of subjects, among whom 24.9% had two or more 
cardiovascular diseases. There are three main findings. Firstly, 
elevated serum PTH levels (SHPT) independently of 25(OH)
D and other parameters of mineral and bone metabolism as 
well as age, sex, smoking status, alcohol consumption, renal 
impairment, hypoalbuminemia, dementia, and HF type were 
associated with 2.68-fold greater prevalence of CVD (for 
hypertension, CAD, history of stroke, and AF 1.97-, 3.43-, 
2.57-, and 1.91-fold, respectively) and predictive of poorer 
short-term outcomes. Secondly, high bone resorption (urinary 
DPD/Cr . 7.5 nmol/µmol) was also a significant independent 
indicator of presence of CVD (OR 2.58).With an increasing 
number of CVDs, mean serum levels of PTH and urinary 
DPD/Cr levels as well as the proportion of patients with 
SHPT and excess bone resorption increased significantly. 
SHPT or excess bone resorption predicted the presence of 
CVD by factors of 17.32 and 9.68, respectively, compared 
to subjects with both these parameters in the normal range. 
Because renal impairment (eGFR , 60 mL/minute/1.73 m2) 
was prevalent (in 48.3% with CVD and in 37.4% without 
CVD) and related to SHPT and DPD/Cr in opposite directions, 
these parameters in combination did not provide additive 
prognostic information. Thirdly, the presence of CVD was 
an independent predictor of both SHPT and high DPD/Cr, 
indicating that links between CVD and osteoporotic HF are 
bidirectional. Our main findings are shown in Figure 2.
PTH elevation
In agreement with numerous previous reports,63–65 vitamin D 
insufficiency was highly prevalent in our HF cohort (about 80%). 
Table 7 Use of cardiovascular medications and serum parathyroid 
hormone and vitamin D status
Drugs PTH,  
pmol/L
P-value 25(OH)D,  
nmol/L
P-value
ACE inhibitors
 Yes 11.1 ± 9.9 38.5 ± 17.0
 No 6.7 ± 4.7 0.001 39.2 ± 18.6 0.849
ArBs
 Yes 6.8 ± 3.8 35.6 ± 19.0
 No 7.8 ± 6.7 0.477 39.8 ± 18.0 0.298
Beta blockers
 Yes 10.1 ± 7.8 36.4 ± 17.9
 No 6.5 ± 5.0 0.015 39.6 ± 15.9 0.882
Ca-channel blockers
 Yes 5.1 ± 2.4 41.6 ± 17.1
 No 7.8 ± 6.5 0.016 38.8 ± 18.4 0.621
Statins
 Yes 7.3 ± 4.7 41.2 ± 21.8
 No 7.7 ± 6.6 0.766 38.6 ± 17.5 0.540
Note: Values in bold indicate statistically significant P values.
Abbreviations: ACE, angiotensin-converting enzyme; ArBs, angiotensin II-
receptor blockers; Ca, calcium; 25(OH)D, 25-hydroxyvitamin D.
LOS > 20 daysMyocardial injury In-hospital death
CKD ≥ 3Phosphate
High DPD/CrSHPTAge
CVD
CalciumVitamin DFemale sex
Short-term outcomes
Figure 2 Diagram showing significant independent relationships (as documented 
by multiple regression analyses) between cardiovascular disease and parameters of 
mineral-bone metabolism, age and sex and short-term outcomes.
Notes: Minus signs imply a negative (inverse) relationship; myocardial injury defined 
as cardiac troponin I rise (.0.06 µmol/L).
Abbreviations: CVD, cardiovascular disease; SHPT, secondary hyperpara-
thyroidism (PTH . 6.8 pmol/l); high DPD/Cr, deoxypyridinoline corrected by 
urinary creatinine excretion . 7.5 nmol/µmol; CKD $ 3, chronic kidney disease 
stage 3 or higher (eGFr , 60 mL/minute/1.73 m2); LOS, length of hospital stay; 
PTH,  parathyroid hormone; eGFR, estimated glomerular filtration rate.
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The mean values of 25(OH)D and the prevalence of vitamin 
D deficiency were similar in patients with and without CVD. 
However, despite similarity in vitamin D status, in patients 
with CVD compared to those without CVD, mean serum PTH 
levels and the prevalence of SHPT were significantly higher, 
and these increased with increasing number of CVDs. Among 
patients with SHPT, 76% had CVD.
According to the traditional view, the consequence of 
vitamin D deficiency is SHPT, leading to bone resorption, 
osteoporosis, and fractures. However, in a substantial per-
centage of subjects with hypovitaminosis D, the serum PTH 
levels were found to be in the reference range. A concept of 
“functional hypoparathyroidism” with a protective role in 
bone health has been proposed.64,66 The prevalence of this 
condition ranges between 16% and 88%.64,67–71 On the other 
hand, in one study of community-dwelling older women, 
vitamin D deficiency (25[OH]D , 50 nmol/L) was found 
in 2%, but elevated PTH (.65 ng/L . 6.9 pmol/L) in 
17.4%.72 A recent analysis of a large general health-care 
database revealed that increased PTH levels are common, 
even in the absence of 25(OH)D deficiency and renal 
dysfunction.73
It has been reported that in the presence of hypovita-
minosis D, subjects with SHPT compared to those without 
SHPT demonstrated lower BMD, higher bone loss and bone 
turnover,64,66,74,75 increased risk of fracture,76 increased sever-
ity of heart failure77 and higher mortality rates.29,43,69,77–79
Contrary to these reports, other researchers in postmeno-
pausal women with altered vitamin D status did not observe 
any difference in hip or spine BMD,68 nor in the incidence 
of HF or vertebral fractures58 associated with PTH levels. 
Increased incidence of vertebral fractures and altered bone 
turnover (including high urinary DPD) has been reported in 
postmenopausal women with vitamin D insufficiency without 
SHPT.56 A recent prospective cohort study of older persons 
found no evidence of an association between PTH and hip or 
any nonspine fractures, as well as between 25(OH)D and any 
nonspine fractures.80 In postmenopausal women with type 2 
diabetes and vitamin D insufficiency, functional hypopara-
thyroidism (not SHPT) was a risk factor for bone fragility.81 
In nursing home residents with type 2 diabetes, decreased 
PTH levels were associated with lower bone turnover and 
hip-fracture risk.24 A U-shaped association between PTH and 
mortality has been reported in a hemodialysis population,82 
while a recent meta-analysis failed to demonstrate consis-
tent associations between PTH and cardiovascular events 
and mortality in CKD.40 Thus, it appears that the existing 
theoretical framework does not fully account for clinical 
 observations, and the pathophysiological role and significance 
of SHPT remain unclear.
Phylogenetic data demonstrated that although PTH plays 
a key role in the development of bony skeleton,83 PTH-like 
peptides and their receptors occurred before the transition 
from an aquatic to a terrestrial environment and not as adapta-
tion to calcium-depleted milieu.84 The PTH gene family was 
identified in cartilaginous fish,85,86 indicating that these genes 
played important metabolic roles other than bone formation 
and before their recruitment to bone formation. The PTH 
receptors are present not only in bones but also in a variety of 
other tissues and organs, including the cardiovascular system 
(cardiomyocytes, vascular smooth muscle, and endothelial 
cells), kidneys, adrenal cortex, pancreas, breast, and skin.87–89 
Not surprisingly, PTH is involved in numerous physiologi-
cal functions independent of vitamin D status and beyond 
calcium regulation, and hyperparathyroidism therefore may 
have profound effects on morbidity and mortality.
Our findings of the association of elevated PTH levels 
with CVD are in line with several (many but not all) afore-
mentioned reports and supported by the following lines 
of evidence. First, in vitro, PTH has direct hypertrophic, 
inotropic,90 and chronotropic91–93 effects on cardiac muscle. 
Second, primary hyperparathyroidism is associated with 
left ventricular hypertrophy,94 aortic valve calcification,95 
significant dysfunction in coronary microcirculation,96 
increased arterial stiffness,97 CAD, hypertension, and 
increased cardiovascular and all-cause mortality.98,99 
 Parathyroidectomy leads to reversal of these effects.27,28,100 
Third, SHPT caused by chronic kidney disease is linked 
to CVD, hypertension, vascular and valvular calcification, 
left ventricular hypertrophy, fibrosis, and dyslipidemia.101 
Fourth, PTH is associated with cardiovascular risk factors 
in the general population.29,73,102,103 Increased PTH levels 
are associated with hypertension,31,104–109 CAD,34,73,102 left 
ventricular hypertrophy,110,111 cardiac arrhythmias,112 heart 
failure,30,33,110,113–116 and insulin sensitivity,117 as well as car-
diovascular and all-cause mortality in patients with87,118,119 
and without chronic kidney disease.29,32,43,70,78,79,120–122
Some studies, however, did not find a link between 
PTH and CAD,8,49,123 left ventricular hypertrophy,124,125 and 
cardiovascular death.126 PTH levels were not predictive 
of cardiovascular events in CKD patients127 and did not 
emerge as a cardiovascular risk factor in adolescents.128 
In primary hyperparathyroidism, parathyroidectomy does 
not improve renal impairment and may have little effect 
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on hypertension prevalence.28,129 In laboratory animals, 
PTH infusion was shown to cause vasodilatation, myo-
cardial cell contraction and regeneration attenuating isch-
emic cardiomyopathy.111,130–132 Although the discrepancy 
between the studies may reflect, at least in part, differences 
in patient characteristics (age, comorbidities, etc), experi-
mental conditions, modes of PTH administration, PTH 
assay methodology, and in the covariates included in the 
multivariate analyses (in some studies, even 25[OH]D has 
not been simultaneously measured), they also indicate the 
complexity of multiple and sometimes contradictory/para-
doxical effects of PTH (and PTHrP) on different signaling 
and metabolic pathways in the cardiovascular system as in 
the bones.49,111,125,133,134
Our analysis of PTH as a continuous variable demon-
strated that increase in serum PTH is associated with CVD, 
confirming the results of the categorical analysis, in which 
an arbitrary cutoff point for SHPT was used. Of note in our 
study, associations of SHPT with CVDs persisted when 
controlling for multiple covariates, including 25(OH)D, 
adjusted calcium, and other parameters of mineral and bone 
metabolism, indicating that pathways linking PTH and CVD 
are independent from and not mediated by the latter. These 
data suggest the possibility that PTH acts on the cardiovas-
cular system through other biological mechanisms besides 
25(OH)D and bone metabolism.
Experimental and clinical studies revealed that multiple 
and complex pathways may be involved in the development 
and progression of CVD in the presence of PTH excess. 
These include direct effects on cardiomyocytes, endothelial 
and smooth-muscle cells,111,135 stimulation of endothelial 
expression of atherosclerotic, inflammatory, and growth136 
factors, reduction of endothelial osteoprotegerin (OPG) 
secretion (a vascular-protective factor that controls vascular 
calcification),137 increase in sympathetic nerve activity (by 
facilitating norepinephrine release),138 increase in circulating 
ionized calcium (because of release from bone and decreased 
renal excretion), decreased expression of the calcium-sensing 
receptor,139 stimulation of renin, angiotensin II, and aldoster-
one synthesis,140–147 indirect effects of PTH-induced hyper-
phoshatemia148 and hyperlipidemia,149 and decreased insulin 
sensitivity.117 Furthermore, the effects of hyperparathyroid-
ism may be amplified by vitamin D insufficiency, as vitamin 
D is known to contribute directly or indirectly to the (patho)
physiological functions mentioned above, such as renin–
angiotensin–aldosterone system (RAAS) activation, insulin 
resistance, and systemic and vascular inflammations.150 
Taken together, it may be postulated that SHPT is a signifi-
cant biomarker of CVD, and in older HF patients predicts 
postoperative myocardial injury, prolonged hospital stay, 
and in-hospital death.
Excessive bone resorption
Our finding that in older HF patients excess bone resorption 
(as defined by high urinary DPD/Cr excretion, the degra-
dation product of the collagen telopeptide cross-linking 
molecule, which is one of the most specific and sensitive 
markers of osteoclastic bone resorption)151–156 independently 
of traditional risk factors is associated with CVD is in 
accordance with the results reported previously. Prospective 
studies,58,157,158 although not all,159 showed that high bone-
resorption markers were predictive of increased risk for 
fractures (including hip) in postmenopausal women. Elevated 
DPD levels predicted a twofold increased risk of cardiovascu-
lar events in men8 and mitral annular calcification in patients 
with renal stone formation.160 Serum bone-resorption markers 
(which showed good correlation with DPD161) predicted an 
increased carotid intima-media thickness in the elderly,162 
arterial stiffness in predialysis CKD,163 cardiovascular and 
all-cause mortality in subjects living in residential care,43 
and in CKD patients.127
The exact mechanism linking CVD and excess bone 
resorption is not known, and appears multifactorial. 
 Accumulating evidence supports the hypothesis that 
CVD and bone resorption share several common cellular, 
metabolic, and signaling pathways. Both form cells in 
atheromatous plaques and bone osteoclasts derived from 
monocyte/macrophage lineage,164,165 and cells resembling 
osteoclasts have been identified in calcified atherosclerotic 
plaques.166–168 The receptor activator of nuclear factor-
 kappaB (RANK), RANK ligand (RANKL), and OPG play 
an essential role in osteoclastogenesis,169 bone remodeling 
and resorption, and an imbalance in the RANK/RANKL/
OPG system caused by hormones (PTH, 1,25[OH]
2
 D, estro-
gens, glucocorticoids), inflammatory cytokines, T-helper 
cells, oxylipids, oxidative stress, and other interrelated 
factors mediates both bone loss and vascular/atheroscle-
rotic calcification.170–180 OPG has recently been proposed 
as a predictor of cardiovascular mortality and  morbidity, 
although its role in CVD is still controversial.180–182 
 Interestingly, in patients with rheumatoid arthritis, etan-
ercept caused a parallel reduction in serum RANKL and 
urinary DPD levels, while urinary NTx and serum OPG 
levels did not change significantly.183
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Bidirectional links between CVD 
and elevated PTH and excess bone 
resorption
Finally, our data indicate a bidirectional link between CVD 
and abnormalities in mineral/bone metabolism characteristic 
for osteoporosis. In older HF patients, both SHPT and excess 
bone resorption are significant independent indicators of pres-
ence of CVD, and CVD is highly predictive of SHPT and/
or high bone resorption. The nature of these associations is 
complex and involves age- and disease-dependent changes, 
declining renal function, and different altered metabolic and 
signaling pathways. New information reveals remarkably 
close interactions between impaired PTH signaling, dys-
regulation of RAAS, RANK/RANKL/OPG system(axis), 
FGF23-α-Klotho complex, and Wnt signaling pathway,184–188 
all of which have important physiological roles in both car-
diovascular and bone health. Recent findings also indicate 
that oxidative stress, hyperlipidemia, oxidized lipids, and 
inflammation reciprocally regulate vascular and bone min-
eralization involving feedback mechanisms interacting with 
PTH and RANKL.5,171,189
Our findings, when considered together with previous 
literature data, suggest that the bidirectional PTH–CVD rela-
tionships may form a vicious circle in which the interaction 
between PTH and RAAS plays an important role.146,147,190 It 
has been hypothesized that in patients with CVD (especially 
with hypertension and chronic heart failure) inappropriate 
activation of the RAAS and salt retention causes marked 
losses of cations (calcium, magnesium) with a consequent 
increase of PTH production, which in turn stimulates RAAS. 
PTH elevation leads to paradoxical intracellular calcium 
overloading, oxidative stress, degeneration of mitochon-
dria followed by cardiomyocyte necrosis and myocardial 
fibrosis.146,190,191 As PTH increases secretion of aldosterone 
from the adrenals directly and indirectly (by activating the 
RAAS),147 this might further contribute to arterial hyper-
tension and cardiovascular injury. In other words, through 
RAAS-mediated mechanism(s) CVD could contribute to and 
be the result of SHPT. Furthermore, animal studies (angio-
tensin II-receptor knockout mice) revealed that the RAAS has 
a physiologic function in bone metabolism, and that signaling 
through angiotensin II receptor negatively regulates bone 
turnover and bone mass.192 Given the lack of data on the status 
of RAAS in our cohort, we may only speculate regarding its 
role in CVD and bone pathology. In our study, the group with 
CVD had a higher proportion of patients with renal impair-
ment (stage CKD . 3), which is known to be associated with 
higher plasma renin activity.193,194 Moreover, multiple logistic 
regression analysis showed that the use of ACE inhibitors 
was significantly and independently associated with elevated 
PTH. This observation may be explained by the fact that use 
of ACE inhibitors is associated with increase in plasma renin 
activity.195,196 Activation of RAAS, both disease-related and 
drug-related, should be considered in future studies among 
factors causing and aggravating SHPT. In the setting of 
CVD and especially with renal impairment, many other 
factors may also contribute to and be a consequence of 
SHPT; these include 1,25(OH)
2
D deficiency, hypocalcemia, 
hyperphosphatemia, downregulated receptors for vitamin D, 
calcium (calcium-censoring receptor), and FGF23 (FGFR1c-
Klotho complex).197 We observed impaired serum phosphate 
homeostasis in our cohort: patients with hypertension and 
CAD as the CVD group in total demonstrated significantly 
elevated serum phosphate levels compared to the non-CVD 
group. Furthermore, there was not only a negative correla-
tion between serum calcium and PTH, but serum calcium 
(inversely) and phosphate (positively) levels were indepen-
dently associated with SHPT.
Clinical implications
Taken together, ours and previous data on bidirectional bone–
cardiovascular regulatory axis suggest the need to revisit 
conventional patterns of care for older patients: all subjects 
with osteoporosis and fractures should be screened for CVD, 
and in patients with CVD the mineral and bone status should 
be determined, as in both conditions clinical signs may be 
absent, making their recognition difficult. Moreover, there 
is increasing evidence that bisphosphonates are effective not 
only in prevention of osteoporotic fractures but also reduce 
cardiovascular and total mortality,198–202 while lipid-lowering 
statins1,203,204 and beta blockers205 may have a positive effect 
on osteoporosis.
On the other hand, it should be emphasized that SHPT 
and excess bone resorption, important pathophysiological 
characteristics linking CVD and osteoporotic fractures, are 
present only in a proportion of HF patients with or without 
CVD, reflecting the disease diversity and significant varia-
tions in the related variables exhibited by individual patients. 
Therefore, identification of the PTH and bone-resorption 
status may improve the diagnostic and prognostic evaluation 
of the patient and might offer opportunities for individualized 
treatment. However, much further work is needed to clarify 
the hierarchy of genetic, environmental, and modulating fac-
tors causing the heterogeneity of both CVD and osteoporotic 
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fractures in regard to PTH and bone-resorption status, and 
to find if a syndrome-specific approach (eg, interventions 
targeting SHPT and/or high DPD/Cr excretion) will improve 
the preventive and therapeutic strategies for these common 
diseases.
Limitations and strengths
Our study has several limitations as well as strengths. First, 
because of the cross-sectional design, the described associa-
tions do not prove causality. Second, the presence of subclini-
cal CVD was not assessed; therefore, the prevalence of CVD 
was probably underestimated and the duration and severity 
of CVD was not analyzed. Third, our results are based on a 
single measurement of mineral/bone metabolism parameters 
on hospital admission, and these may change and fluctuate. 
Fourth, our cohort was of predominantly white Caucasians, 
so the results may not be applicable to other races or ethnic 
groups. The relatively large number of consecutive older 
HF patients that reflects a real-life situation, prospective 
follow-up for short-term outcomes, simultaneous estimation 
of 25(OH)D, PTH, calcium, phosphate, magnesium, and four 
bone-turnover markers levels, and adjustments for multiple 
confounding factors (sociodemographic, eGFR, albumin, 
comorbidities) strengthen our results. On the other hand, in 
multivariate regression analysis, multiple comparisons may 
potentiate the significance of multicollinearity phenomena. 
However, the variance inflation factor in all our models 
(Tables 4–6) was between 1.14 and 1.02, indicating that the 
amount of multicollinearity was not significant.
Conclusion
In older HF patients, CVD and vitamin D deficiency are 
highly prevalent (in about 63% and 80%, respectively). 
Although serum 25(OH)D levels in subjects with and with-
out CVD were similar, serum PTH levels and urinary DPD/
Cr excretion as well as the prevalence of SHPT and excess 
bone resorption were significantly higher in patients with 
CVD. Both SHPT and high DPD/Cr were strong independent 
indicators of presence of CVD and vice versa. Presence of 
CVD was predictive of postoperative myocardial injury, 
while SHPT was also an independent predictor of prolonged 
hospital stay and in-hospital death. These findings suggest 
that: (1) CVD and osteoporotic fractures share common 
pathogenetic mechanisms, (2) elevated levels of PTH and 
hypovitaminosis D affect the cardiovascular system and 
bones through multiple biochemical mechanisms and path-
ways, (3) SPTH and high urinary DPD/Cr excretion may be 
used as biomarkers of both osteoporosis and CVD and be 
helpful for individualized preventive and therapeutic inter-
ventions, and (4) patients with one of these diseases should 
be evaluated and treated for the other.
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